Dyadic International, Inc. (DYAI)Healthcare | Biotechnology | Jupiter, United States | NasdaqCM
0.83 USD
+0.01
(1.220%)
⇧
(April 22, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | April 18, 2026, 10:19 p.m. EDT
DYAI is a high-risk biotech shell facing an existential threat from dual Nasdaq listing deficiencies; despite a target price suggesting massive upside potential, the fundamentals are collapsing (shrinking revenue, negative growth, and net losses). The absence of options flow confirms that capital is on the sidelines waiting for a resolution rather than betting on the outcome, making this a dangerous trap for trend-followers. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.063408 |
| AutoETS | 0.074382 |
| AutoARIMA | 0.074452 |
| MSTL | 0.074458 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 54% |
| H-stat | 3.13 |
| Ljung-Box p | 0.003 |
| Jarque-Bera p | 0.483 |
| Excess Kurtosis | -0.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 410.632 |
| Revenue per Share | 0.095 |
| Market Cap | 30,244,124 |
| Forward P/E | -2.59 |
| Beta | 1.21 |
| Profit Margins | -238.31% |
| Website | https://www.dyadic.com |
As of April 18, 2026, 10:19 p.m. EDT: Options activity is extremely thin, with minimal volume in both ATM and OTI expiry. Call open interest aggregates 64 contracts at $1.31 ATM, concentrated in the 1-month and 3-month expirations, suggesting negligible speculative positioning for upside momentum. The lack of significant put or call flow indicates a standoff or lack of conviction from retail/hedge fund participants. Implied volatility is flat (0.50), reflecting a market that is not pricing in a significant near-term move despite the delisting news.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3140496 |
| Address1 | 1,044 North U.S. Highway One |
| Address2 | Suite 201 |
| All Time High | 10.98 |
| All Time Low | 0.05 |
| Ask | 1.07 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 46,230 |
| Average Daily Volume3 Month | 69,263 |
| Average Volume | 69,263 |
| Average Volume10Days | 46,230 |
| Beta | 1.211 |
| Bid | 0.5929 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 0.034 |
| City | Jupiter |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.83 |
| Current Ratio | 2.684 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.85 |
| Day Low | 0.8189 |
| Debt To Equity | 410.632 |
| Display Name | Dyadic |
| Earnings Call Timestamp End | 1,774,472,400 |
| Earnings Call Timestamp Start | 1,774,472,400 |
| Earnings Timestamp | 1,774,468,800 |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 9.055 |
| Enterprise Value | 27,983,796 |
| Eps Forward | -0.32 |
| Eps Trailing Twelve Months | -0.23 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 561 743 8343 |
| Fifty Day Average | 0.8218 |
| Fifty Day Average Change | 0.00819999 |
| Fifty Day Average Change Percent | 0.009978085 |
| Fifty Two Week Change Percent | -31.40496 |
| Fifty Two Week High | 1.35 |
| Fifty Two Week High Change | -0.52000004 |
| Fifty Two Week High Change Percent | -0.3851852 |
| Fifty Two Week Low | 0.65 |
| Fifty Two Week Low Change | 0.18 |
| Fifty Two Week Low Change Percent | 0.2769231 |
| Fifty Two Week Range | 0.65 - 1.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,200,493,800,000 |
| Float Shares | 30,494,822 |
| Forward Eps | -0.32 |
| Forward P E | -2.59375 |
| Free Cashflow | -4,524,691 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.24931999 |
| Gross Profits | 770,485 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.25473 |
| Held Percent Institutions | 0.16792 |
| Implied Shares Outstanding | 36,438,703 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida. |
| Long Name | Dyadic International, Inc. |
| Market | us_market |
| Market Cap | 30,244,124 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_4272801 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -7,364,628 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 29,883,380 |
| Number Of Analyst Opinions | 2 |
| Open | 0.819 |
| Operating Cashflow | -5,702,221 |
| Operating Margins | -2.69648 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 561 743 8333 |
| Previous Close | 0.82 |
| Price Hint | 4 |
| Price To Book | 24.411762 |
| Price To Sales Trailing12 Months | 9.78665 |
| Profit Margins | -2.38311 |
| Quick Ratio | 2.291 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 1.219511 |
| Regular Market Day High | 0.85 |
| Regular Market Day Low | 0.8189 |
| Regular Market Day Range | 0.8189 - 0.85 |
| Regular Market Open | 0.819 |
| Regular Market Previous Close | 0.82 |
| Regular Market Price | 0.83 |
| Regular Market Time | 1,776,888,000 |
| Regular Market Volume | 102,157 |
| Return On Assets | -0.44941002 |
| Return On Equity | -3.9779801 |
| Revenue Growth | -0.308 |
| Revenue Per Share | 0.095 |
| Sand P52 Week Change | 0.30140376 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 36,438,703 |
| Shares Percent Shares Out | 0.0036000002 |
| Shares Short | 130,008 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 94,848 |
| Short Name | Dyadic International, Inc. |
| Short Percent Of Float | 0.0046 |
| Short Ratio | 1.21 |
| Source Interval | 15 |
| State | FL |
| Symbol | DYAI |
| Target High Price | 9.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 7.0 |
| Total Cash | 7,320,992 |
| Total Cash Per Share | 0.201 |
| Total Debt | 5,060,665 |
| Total Revenue | 3,090,345 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.23 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.93845 |
| Two Hundred Day Average Change | -0.108449996 |
| Two Hundred Day Average Change Percent | -0.11556289 |
| Type Disp | Equity |
| Volume | 102,157 |
| Website | https://www.dyadic.com |
| Zip | 33,477-5094 |